- Home
- ATEX vs CMPS Comparison
ATEX vs CMPS Comparison
Compare ATEX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- CMPS
- Stock Information
- Founded
- ATEX 1997
- CMPS 2020
- Country
- ATEX United States
- CMPS United Kingdom
- Employees
- ATEX N/A
- CMPS N/A
- Industry
- ATEX Telecommunications Equipment
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- CMPS Health Care
- Exchange
- ATEX Nasdaq
- CMPS Nasdaq
- Market Cap
- ATEX 408.7M
- CMPS 364.9M
- IPO Year
- ATEX N/A
- CMPS 2020
- Fundamental
- Price
- ATEX $21.13
- CMPS $4.39
- Analyst Decision
- ATEX Buy
- CMPS Strong Buy
- Analyst Count
- ATEX 2
- CMPS 7
- Target Price
- ATEX $64.00
- CMPS $17.00
- AVG Volume (30 Days)
- ATEX 174.1K
- CMPS 2.1M
- Earning Date
- ATEX 08-12-2025
- CMPS 07-31-2025
- Dividend Yield
- ATEX N/A
- CMPS N/A
- EPS Growth
- ATEX N/A
- CMPS N/A
- EPS
- ATEX N/A
- CMPS N/A
- Revenue
- ATEX $6,031,000.00
- CMPS N/A
- Revenue This Year
- ATEX $5.17
- CMPS N/A
- Revenue Next Year
- ATEX $2.92
- CMPS N/A
- P/E Ratio
- ATEX N/A
- CMPS N/A
- Revenue Growth
- ATEX 43.90
- CMPS N/A
- 52 Week Low
- ATEX $20.61
- CMPS $2.25
- 52 Week High
- ATEX $42.91
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- ATEX 30.74
- CMPS 55.62
- Support Level
- ATEX $21.73
- CMPS $4.27
- Resistance Level
- ATEX $22.26
- CMPS $4.79
- Average True Range (ATR)
- ATEX 0.83
- CMPS 0.34
- MACD
- ATEX 0.10
- CMPS 0.00
- Stochastic Oscillator
- ATEX 22.18
- CMPS 54.02
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.